Results 201 to 210 of about 158,092 (291)
A commentary on "Assessing kidney outcomes in childhood-onset lupus nephritis: role of National Institutes of Health-modified histological indices". [PDF]
Ma Y, Zhu Y.
europepmc +1 more source
Nephrotic‐range proteinuria during pregnancy is not always preeclampsia. This case illustrates a steroid‐responsive tip‐variant podocytopathy with normal angiogenic biomarkers (sFlt‐1/PlGF), supporting a non‐placental origin. Renal biopsy confirmed the diagnosis, while concurrent CMV infection may have acted as a potential immunologic trigger ...
Sierra Acuña Ximena Rosario +1 more
wiley +1 more source
Utility of Urinary β2-Microglobulin for Detection of Renal Sarcoidosis Without Pulmonary Involvement: A Case Report. [PDF]
Oue Y +4 more
europepmc +1 more source
GDM with and without DM was significantly associated with an increased risk of maternal CKD. GDM with DM had a synergistic effect on maternal CKD risk. Women who experience GDM during their pregnancy, especially those who later develop diabetes, should be well informed about their long‐term risk of kidney disease.
Mansour Bahardoust +7 more
wiley +1 more source
Vedolizumab induced acute interstitial nephritis. [PDF]
Fernandes D +3 more
europepmc +1 more source
The Current Use and Future Perspectives of Biosimilars in Pediatric Healthcare: A Narrative Review
ABSTRACT Background and Aims The integration of biosimilars into pediatric healthcare represents a significant evolution in treatment accessibility and cost‐effectiveness. Biosimilars—biological products highly similar to already approved biologics, have emerged as promising alternatives for managing chronic and rare pediatric conditions, including ...
Zubaier Ahmed +6 more
wiley +1 more source
A novel surface plasmon resonance approach to assess anti-dsDNA antibody kinetics and disease severity in systemic lupus erythematosus. [PDF]
Nagant C +6 more
europepmc +1 more source
Is Therapeutic Abortion Scientifically Justified? [PDF]
Heffernan, Roy J., Lynch, William A.
core +1 more source
What's new? The combination of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma has demonstrated durable response and tolerability in clinical trials. However, inclusion criteria for clinical studies are restrictive, and patients in the real‐world setting tend to have more comorbidities.
Hendrik Dinkel +21 more
wiley +1 more source

